A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer

Annals of Oncology

Volumn 22, Issue 3, 2011, Pages 603-608

  Heinemann, V ^a   di Gioia, D ^a   Vehling Kaiser, U ^b   Harich, H D ^b   Heinrich, B ^c   Welt, A ^d   Ziske, C ^e   Deutsch, G ^f   Pihusch, R ^g   Kolbl H ^h   Hegewisch Becker, S ⁱ   Michl, M ^a   Stemmler, H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Oncological Practice   (Germany)

^c Oncological Practice   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Troisdorf   (Germany)

^f University of Mainz ^*  (Germany)

^g Oncological Practice   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ Haematology/Oncology Clinic   (Germany)

Author keywords

HER2; Metastatic breast cancer; Oral vinorelbine; Trastuzumab

Indexed keywords

NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE OVEREXPRESSION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HER2 GENE; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH PAIN; STOMATITIS; THROMBOCYTOPENIA; VISCERAL METASTASIS;

EID: 79952026342     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq409     Document Type: Article

References (34)

1. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
2. Revillon F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
3. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27(34): 5838-5847.
4. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
5. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
6. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(7): 1800-1808.
7. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19(10): 2587-2595.
8. Bartsch R, Wenzel C, Altorjai G et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25(25): 3853-3858.
9. Pegram MD, Pienkowski T, Northfelt DW et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 2004; 96(10): 759-769.
10. O'Shaughnessy JA, Vukelja S, Marsland T et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004; 5(2): 142-147.
11. Potier P. The synthesis of navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989; 16 (Suppl 4): 2-4.
12. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11(7): 1245-1252.
13. Romero A, Rabinovich MG, Vallejo CT et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12(2): 336-341.
14. Martin M, Ruiz A, Muñoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8(3): 219-225.
15. Nistico C, Garufi C, Milella M et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000; 59: 223-229.
16. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96(10): 739-749.
17. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19(10): 2722-2730.
18. Jahanzeb M, Mortimer JE, Yunus F et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002; 7(5): 410-417.
19. Bunnell CA, Burstein HJ, Kelly-Marcom P et al. Multicenter phase II study of trastuzumab (T) and vinorelbine (V) as first-line therapy for HER2 overexpressing metastatic breast cancer. Ann Oncol 2002; 13: 50 (Abstr 180P).
20. Chan A, Martin M, Untch M et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006; 95(7): 788-793.
21. Bayo J, Mayordomo JI, Sanchez-Rovira P et al. Trastuzumab and vinorelbine combination in the treatment of HER2-positive metastatic breast cancer. J Clin Oncol 2004; 22(14S): 763; ASCO Annual Meeting Proceedings (Post-Meeting Edition).
22. Bernardo G, Palumbo R, Bernardo A et al. Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2004; 22(14S): 731 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
23. Schilling G, Bruweleit M, Harbeck N et al. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs 2009; 27(2): 166-172.
24. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15(1): 110-115.
25. Catania C, Didier F, Leon ME et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005; 92(3): 265-272.
26. Amadori D, Koralewski P, Tekiela A et al. Efficacy and safety of navelbine oral (NVBo) in first-line metastatic breast cancer (MBC). Eur J Cancer 2001; 37: 22 (Abstr 713).
27. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vinorelbine in firstline advanced breast cancer chemotherapy. J Clin Oncol 2003; 21(1): 35-40.
28. Trillet-Lenoir V, Sommer H, Delozier T et al. Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer 2004; 2 (Suppl 3): 137.
29. Bartsch R, Wenzel C, Altorjai G et al. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007; 102(3): 375-381.
30. Bernardo G, Palumbo R, Bernardo A et al. Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: final results of an extended phase II trial. Eur J Cancer Suppl 2008; 6(7): 175.
31. Catania C, Medici M, Magni E et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 2007; 18(12): 1969-1975.
32. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
33. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10(1): 1-10.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.